Login
Vivani Medical, Inc. logo

Vivani Medical, Inc.

vivani.com

What Do They Do?

Develops miniature, removable drug implants designed to deliver long-acting medicines for chronic diseases in people and companion animals.

Who Are Their Customers?

Vivani develops implant candidates itself or with pharmaceutical partners. For commercialization, it plans to work with a large pharmaceutical company or use its own sales network, distributors or contract sales teams.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −11% (Loss)
vs −$6.5M in Q3 FY2025
  • Nov 11, 2026 Cortigent merger with ClearOne awaits final regulatory approval The transaction would make Cortigent a ClearOne subsidiary; the expected close remains subject to final regulatory approval.

Broader implant portfolio The older report centered on an implant for type two diabetes; the latest describes implants for weight management, diabetes and companion animals, while prioritizing the obesity program.

Neurostimulation assets moved into Cortigent The older report described neurostimulation as a division with strategic options under review; the latest says those assets were contributed to Cortigent and outlines potential routes to make it a separate company.

Who Do They Compete With?

Competes with Lilly, Novo Nordisk, AstraZeneca, Sanofi, Altimmune, Alveus, Amgen, Ascletis Pharma, Biomea, D&D Pharmatech, Fractyl Health, Gan & Lee, Innovent, Chugai, Mardigal, CSPC, Merck, Mindrank, OPKO Health, and Pfizer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support